Results 131 to 140 of about 46,178 (264)

APOE genotype and the effect of statins on lipid outcomes: A meta‐analysis

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1268-1286, May 2026.
Aim APOE genotype may affect statin therapy response. We conducted a meta‐analysis to update and quantify this association across various outcomes. Methods We searched seven databases (MEDLINE, Scopus, Web of Science, the Cochrane Library, APA PsycINFO, CINAHL Plus and ClinicalTrials.gov) on 9 May 2024.
Innocent G. Asiimwe, Tsegay Gebru, Andrea L. Jorgensen, Munir Pirmohamed, on behalf of the Multimorbidity Mechanism and Therapeutics Research Collaborative   +4 more
wiley   +1 more source

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. [PDF]

, 2019
Many risk genes for the development of Alzheimer's disease (AD) are exclusively or highly expressed in myeloid cells. Microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for their survival.
Bollag, Gideon, Broome, Stephanie, Burton, Elizabeth A, Crapser, Joshua, Green, Kim N, Habets, Gaston, Hohsfield, Lindsay A, Ibrahim, Prabha, Lin, Jack, Nespi, Marika, Phan, Nicole Y, Rymar, Andrey, Severson, Paul L, Singh, Parmveer, Spangenberg, Elizabeth, Spevak, Wayne, Tsang, Garson, Walters, Jason, West, Brian L, Zhang, Chao, Zhang, Jiazhong, Zhang, Ying   +21 more
core  

APOE genotype differentially modulates effects of anti-Aβ, passive immunization in APP transgenic mice [PDF]

, 2017
BACKGROUND: APOE genotype is the foremost genetic factor modulating β-amyloid (Aβ) deposition and risk of sporadic Alzheimer’s disease (AD). Here we investigated how APOE genotype influences response to anti-Aβ immunotherapy.
Baquero-Buitrago, Jairo, Holtman, David M, Kim, Jungsu, Lopez-Contreras, Jennifer, Pankiewicz, Joanna E, Sadowski, Martin J, Sanchez, Sandrine, Sullivan, Patrick M   +7 more
core   +2 more sources

Antithrombotic Therapy After Intracerebral Hemorrhage: Real‐World Evidence for In‐Hospital Resumption

CNS Neuroscience &Therapeutics, Volume 32, Issue 5, May 2026.
In‐hospital resumption of antithrombotic therapy after acute spontaneous intracerebral hemorrhage was associated with a reduced risk of ischemic events and no excessive bleeding risk. ABSTRACT Background and Purpose Patients with intracerebral hemorrhage (ICH) who require antithrombotic therapy (AT) face competing risks of recurrent bleeding and ...
Shengde Li, Tian Qu, Xiang Zhou, Qi Miao, Jun Ni, Bin Peng   +5 more
wiley   +1 more source

An unexpected discovery of a novel potentially pathogenic APP gene variant: a case report of slowly progressive Alzheimer’s disease with prominent cerebral amyloid angiopathy

Frontiers in Neuroscience
Amyloid precursor protein (APP) plays an essential role in brain function and development. Variants in the APP gene are associated with both familial Alzheimer’s disease and cerebral amyloid angiopathy. We report a case of early onset, slowly progressive
Matyas Sykora, Matyas Sykora, Matyas Sykora, Marie Harmackova, Eva Parobkova, Eva Parobkova, Robert Rusina, Robert Rusina, Radoslav Matěj, Radoslav Matěj, Radoslav Matěj   +10 more
doaj   +1 more source

Beta-Amyloid pathology in human brain microvessel extracts from the parietal cortex: Relation with cerebral amyloid angiopathy and Alzheimer’s Disease

Acta Neuropathologica, 2019
Several pieces of evidence suggest that blood–brain barrier (BBB) dysfunction is implicated in the pathophysiology of Alzheimer’s disease (AD), exemplified by the frequent occurrence of cerebral amyloid angiopathy (CAA) and the defective clearance of Aβ ...
P. Bourassa, C. Tremblay, J. Schneider, D. Bennett, F. Calon   +4 more
semanticscholar   +1 more source

Alzheimer's disease and mixed pathologies as a hidden contributor to fatal hypothermia: A large‐scale forensic autopsy‐based study

Brain Pathology, Volume 36, Issue 3, May 2026.
We investigated neuropathological manifestations of hypothermia in 168 cases. Patients aged 65 years or more constituted 80% of the total cohort. Alzheimer's disease was the most common comorbidity, affecting 40% of all patients. Abstract There is a paucity of autopsy‐based studies providing detailed neuropathological characteristics of fatal ...
Shojiro Ichimata, Koji Yoshida, Ryo Tanaka   +2 more
wiley   +1 more source

Immunotherapy with ponezumab for probable cerebral amyloid angiopathy

Annals of Clinical and Translational Neurology, 2019
Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β‐amyloid fragments leading to cerebrovascular dysfunction and other brain injuries.
C. Leurent, James A. Goodman, Yao Zhang, P. He, J. Polimeni, M. Gurol, Monica Lindsay, Linda Frattura, U. S. Sohur, A. Viswanathan, M. Bednar, Eric E. Smith, Charlotte David John Sandra Elizabeth Lawrence Sterling Cath Cordonnier Werring Black Honig Klijn Lee Restrepo, C. Cordonnier, D. Werring, S. Black, L. S. Honig, C. Klijn, Jin-moo Lee, L. Restrepo, C. Kase, S. Savitz, S. Greenberg   +22 more
semanticscholar   +1 more source

Vessel‐associated microglia are differentially activated and distributed in relation to systemic infection and Alzheimer's disease

Brain Pathology, Volume 36, Issue 3, May 2026.
This post‐mortem study revealed an increased density of vessel‐associated microglia (VAM) in the temporal lobe in systemic infection and Alzheimer's disease. VAM density was related to brain cytokine levels and markers of cerebrovascular dysfunction and BBB leakage indicating that activated VAM contributes to neurovascular injury in Alzheimer's disease.
Oliver Milner, Robert A. Fisher, Daniel J. Asby, Stephen Cross, Delphine Boche, J. Scott Miners   +5 more
wiley   +1 more source

Practical Recommendations for Anticoagulation in Patients With Atrial Fibrillation

European Journal of Clinical Investigation, Volume 56, Issue 5, May 2026.
Oral anticoagulation (OAC) reduces stroke risk by at least two thirds and mortality by one fourth. The threshold for net clinical benefit of OAC is met when stroke risk exceeds 1%–2% per year. Direct oral anticoagulants (DOACs) are preferred to vitamin K antagonists (VKAs) in most patients, including in the elderly and chronic kidney disease ...
Nicolas Johner, Baris Gencer
wiley   +1 more source